| Biosimilars Aren't So Darn Easy Derek Lowe submits: This post drew a lot of comments here about how the big companies are going after follow-on biologic drugs. As a late-2008 article put it: Merck already has one FOB in clinical development: a pegylated erythropoietin for anemia similar to Amgen's Aranesp (darbapoetin alfa) called MK-2578, which is being developed using a sugar-modification technology the pharma obtained via its 2006 purchase of GlycoFi. The company hopes to launch its EPO product in dialysis and pre-dialysis patients with chronic kidney disease in 2012.Complete Story » seekingalpha.com |
Rise of Stand-up Paddle Boards You can do it on lakes and still waters and proponents say it's one of the best all-around workouts. online.wsj.com |
Ironwood Pharmaceuticals Provides Second Quarter 2010 Investor Update (Business Wire) CAMBRIDGE, Mass.----Ironwood Pharmaceuticals, Inc. today provided an update on its business activities for the second quarter of 2010. us.rd.yahoo.com |
Principal Financial Quits Writing Health-Care Policies Financial services provider Principal Financial Group is exiting the health-insurance business in an early sign of expected industry consolidation as the impact of the health overhaul becomes clearer. online.wsj.com |
Laboratory Corporation of America® Holdings Announces 2010 Third Quarter Results [Business Wire] - Laboratory Corporation of America® Holdings today announced results for the quarter ended September 30, 2010. us.rd.yahoo.com |